Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Phase I/II Dose Escalation Trial of Stereotactic Body Radiation Therapy in Combination With Radiomodulating Agent GC4419 in Locally Advanced Pancreatic Adenocarcinoma

NCT03340974 is registered in ClinicalTrials.gov with Galera Therapeutics, Inc. as lead sponsor.

NCT NCT03340974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03340974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Phase I/II Dose Escalation Trial of Stereotactic Body Radiation Therapy in Combination With Radiomodulating Agent GC4419 in Locally Advanced Pancreatic Adenocarcinoma
Lead sponsor
Galera Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 12, 2018
Completion date
May 26, 2021
Enrollment
42 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, stereotactic body radiation therapy